ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0729

Morbidity of JIA-associated Uveitis: Half of Patients Despite Systemic Treatment Still Show Ocular Damage During a Long-term Follow-up
Abstract Number: 0730

To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
Abstract Number: 0731

Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U
Abstract Number: 0732

Changing Evidence over Time: Updated Meta-analysis Regarding Anti-TNF Efficacy in Childhood Chronic Uveitis
Abstract Number: 0733

Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis
Abstract Number: 0734

Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Abstract Number: 0735

Paediatric Sarcoidosis: Phenotype of a Retrospective Cohort of Biopsy-proven Patients
Abstract Number: 0736

Identification of Salient Resilience Domains Among Adolescents with Chronic Musculoskeletal Pain and Their Parents
Abstract Number: 0737

“It’ll Go Away. There’s Nothing Wrong with you:” the Experience of Pain-Related Stigma Among Adolescents with Pain Amplification Syndrome
Abstract Number: 0738

Systemic Administration of Novel Hydroxyl Dendrimers to Target Inflammation in Arthritic Tissues
Abstract Number: 0739

Toll-like Receptor Inhibitor Peptide Improves the Clinical, Immunologic, and Pathologic Manifestations of Systemic Lupus Erythematosus
Abstract Number: 0740

Card9 Promotes Th17-mediated Arthritis and Spondylitis via Control of Acute Pathogenic Neutrophil Responses in SKG Mice
Abstract Number: 0741

Constitutive Inhibitor Kappa B (IκB) Kinase 2 (IKK2) Activation Induces an Inflammatory State in Fibroblast-Like Synoviocytes
Abstract Number: 0742

Effect of IA OnabotulinumtoxinA and Vanilloids on Substance P and Neurokinin 1 Receptor Expression in the Dorsal Root Ganglia of Mice with Monoarthritis
Abstract Number: 0743

Higher Baseline Fine-Specificity ACPAs Predict Greater Treatment Response with Abatacept + MTX versus MTX Monotherapy in Seropositive RA: A Post Hoc Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].